Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 79 people across four groups: 21 received a placebo (a dummy treatment with no active ingredient), 18 received a 10 mg dose of GSK962040, 18 received a 50 mg dose, and 22 received a 125 mg dose. The trial was measuring how quickly the stomach emptied its contents in people who took the study drug compared to those who took the placebo. Stomach emptying was tracked using a breath test that detected a harmless, non-radioactive marker added to a test meal. The main outcome being measured was the time it took for the stomach to empty half its contents (called the "gastric half emptying time"), recorded in minutes. The reported data shows that at the start of the study (Day 1, before dosing), the average time for the stomach to empty halfway was around 131 minutes for the placebo group, 107 minutes for the 10 mg group, 118 minutes for the 50 mg group, and 131 minutes for the 125 mg group. By Day 28, those figures were reported as approximately 124 minutes (placebo), 107 minutes (10 mg), 105 minutes (50 mg), and 99 minutes (125 mg). The reported data also shows that small changes in blood pressure, heart rate, and heart electrical activity (measured by ECG) were recorded across all groups, with no single group showing a notably large or consistent change. In terms of unwanted medical events during the trial ("adverse events"), 13 people in the placebo group, 14 in the 10 mg group, 13 in the 50 mg group, and 18 in the 125 mg group experienced at least one such event. Serious adverse events were reported in 1 person in the placebo group, 0 in the 10 mg group, 1 in the 50 mg group, and 0 in the 125 mg group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Gastroparesis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Type 1 or Type 2 Diabetes, with your blood sugar levels reasonably controlled (a specific blood test result below 10%)
- You are between 18 and 80 years old
- You have been diagnosed with gastroparesis (slow stomach emptying), confirmed by a specific breath test at the screening stage
- You have had symptoms of gastroparesis for at least 3 months, such as feeling very full after eating, feeling full very quickly, or feeling sick after meals — and your symptoms are at least mild but not more than severe, based on a daily symptom diary kept for at least 7 days before the study begins
- You are a woman who either cannot become pregnant (due to tubal ligation, hysterectomy, or being post-menopausal) or who agrees to use an approved form of contraception before, during, and for at least 5 days after taking the study medication
- You are a man who agrees to use an approved form of contraception from the first dose through at least 5 days after the last dose
- Your body weight falls within a healthy range for your height (BMI between 18 and 35)
- You have never had your stomach surgically removed, have not had major stomach surgery, and have had no bowel blockages or narrowings in the past 12 months
- Any regular medications you take have been at a stable dose for at least 3 weeks (routine insulin adjustments are allowed)
- Your kidneys are functioning at an adequate level, based on a blood test (confirm with trial site)
- Your heart's electrical activity (measured by an ECG) is within acceptable limits (confirm with trial site)
- Your liver function blood tests are within acceptable limits
- You are able to understand and sign a consent form agreeing to take part
Who may not be able to join:
- You currently have a sudden, severe stomach or gut infection
- You have a gastric pacemaker (a device implanted to help your stomach move)
- You are currently being fed through a drip or tube directly into your bloodstream or gut on a long-term basis
- You are severely dehydrated
- In the last 6 weeks, your diabetes has been poorly controlled — for example, you have had a very low blood sugar requiring medical help, a dangerous diabetic episode (ketoacidosis), or a hospital admission related to your diabetes
- You have severe nerve damage affecting your heart and circulation, for example repeated fainting episodes in the last 6 months
- You have a history of an eating disorder such as anorexia, binge eating, or bulimia
- You have taken medications that affect how your stomach or upper gut moves, or that affect appetite, within one week before the study (such as certain gut-motility drugs, some antibiotics like erythromycin, or certain diabetes injections — confirm with trial site)
- You regularly use opiate-based pain medications (such as morphine or codeine)
- You are taking any other medications listed as prohibited by the trial within certain timeframes before starting (confirm with trial site)
- You have a significant ongoing condition affecting your gut, liver, or kidneys that the doctor feels would make participation unsafe
- You have taken part in another clinical trial and received an experimental medication within the past 30 days (or longer, depending on that medication)
- You have a known allergy or sensitivity to any of the study medications or their ingredients
- Participating in this study would require you to donate more than 500 mL of blood within a 56-day period
- You are pregnant or receive a positive pregnancy test at any point before starting the study
- You are currently breastfeeding
- You have a current or long-term history of liver disease, or a known liver or bile duct problem (except for a harmless condition called Gilbert's syndrome or gallstones that are not causing symptoms)
- You have recently tested positive for Hepatitis B or Hepatitis C (within the past 3 months)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: GSK Clinical Trials, GlaxoSmithKline
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Gastric Half Emptying Time (GEt1/2)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.